- Company
- Koselugo reattempts insurance benefit in neurofibromatosis
- by Eo, Yun-Ho May 10, 2022 06:07am
- The neurofibromatosis treatment Koselugo is once again making an attempt to receive insurance benefits in an area that has no available treatment options, According to industry sources, AstraZeneca has applied for the insurance reimbursement of its new neurofibromatosis drug Koselugao (selumetinib) recently. Koselugo is indicated for ‘th
- Company
- Powder-type child antipyretic analgesics have been released
- by May 10, 2022 06:07am
- Johnson & Johnson Korea (CEO Baek Joon-hyuk) announced on the 9th that it has released the first powder-type children's antipyretic painkiller Children's Tylenol powder 160 mg in Korea. Children's Tylenol powder has various effects such as headache, neuralgia, muscle pain, sprain pain, menstrual pain, toothache, and joint pain, as well as fe
- Company
- Sales of generic for Galvus are not affected
- by Kim, Jin-Gu May 10, 2022 06:07am
- A reversal occurred once again in the patent dispute for the DPP-4 inhibitor-based diabetes treatment Galvus. The original signing Novartis won the remand hearing that took place after the Supreme Court's dismissal. The pharmaceutical industry believes that the decision will not have a significant impact on sales of generic for Galvus, which
- Company
- The diagnosis of rheumatoid arthritis has been activated
- by Eo, Yun-Ho May 9, 2022 06:04am
- The treatment environment for rheumatoid arthritis has improved significantly. As the diagnosis became accurate, it increased, and the application of the new drug developed greatly. Recently, the number of patients has been steadily increasing every year as the diagnosis of rheumatoid arthritis has been activated in Korea. The HIRA updates
- Company
- “Will become a CRO specializing in cell·gene therapy”
- by Lee, Tak-Sun May 9, 2022 06:04am
- “I believe the cell·gene therapy market will expand the greatest among biopharmaceuticals. The number of new clinical trials entering the field increased over threefold from 2016, and the role of CROs that have strengths in conducting clinical trials for cell· gene-based therapies will further increase in the coming future.” Director
- Company
- Companies reattempt to avoid Dukarb's patent in 2nd trial
- by Kim, Jin-Gu May 9, 2022 06:03am
- Companies that have failed to challenge the patent of Boryung’s antihypertensive combo drug ‘Dukarb (fimasartan+amlodipine)’ are continuing on their challenge with a second trial. As the companies are also working to invalidate the patent apart from the trial being conducted to avoid the patent, this two-track challenge on a single p
- Company
- GLP-1 diabetes drugs are being released one after another
- by May 9, 2022 06:03am
- Novonodisc is expected to change the market for type 2 diabetes treatment as GLP-1 similarity products are released one after another. Novonodisc received domestic approval for Rybelsus (Semaglutide) on the 2nd following Ozempic on the 28th of last month. Ozempic is a long-lasting injection administered once a week, and Rybelsus is a drug tha
- Company
- Sales of Losartan are plummeting due to the impurity crisis
- by Chon, Seung-Hyun May 9, 2022 06:03am
- The prescription market for the hypertension drug "Losartan" has shrunk significantly. It is analyzed that a large number of prescription gaps occurred due to detection of excess impurities at the end of last year. According to UBIST, a pharmaceutical research agency, on the 2nd, the outpatient prescription amount of Losartan-containing drugs in
- Company
- Breast cancer supplement Nerlynx is available in hospitals
- by Eo, Yun-Ho May 6, 2022 05:46am
- Breast cancer supplement Nerlynx has become available in hospitals. According to related industries, Tyrosine kinase inhibitor Nerlynx (Neratinib), which inhibits Bixink's HER2 protein, passed the Drug Committee (DC) of medical institutions such as Seoul National University Hospital. However, as it is still non-reimubrsement, it is expecte
- Company
- Hospitals Busy Introducing Kymriah
- by Moon, sung-ho May 6, 2022 05:45am
- The full-fledged administration of Kymriah, a Korean Novartis CAR-T treatment called an "ultra-high-priced anticancer drug," has begun. Hospitals have also become busy as the administration of treatments at four large hospitals in Korea has begun in earnest. At the beginning of last year's domestic approval, it was a wait-and-see attitude, bu
